This company listing is no longer active
ALONC Stock Overview
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oncodesign Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.42 |
| 52 Week High | €14.64 |
| 52 Week Low | €7.83 |
| Beta | 1.33 |
| 1 Month Change | 0.14% |
| 3 Month Change | 1.55% |
| 1 Year Change | 57.25% |
| 3 Year Change | 63.12% |
| 5 Year Change | 25.39% |
| Change since IPO | 113.63% |
Recent News & Updates
Shareholder Returns
| ALONC | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | -0.6% |
| 1Y | 57.3% | -31.6% | -4.0% |
Return vs Industry: ALONC exceeded the French Biotechs industry which returned -61% over the past year.
Return vs Market: ALONC exceeded the French Market which returned -9.6% over the past year.
Price Volatility
| ALONC volatility | |
|---|---|
| ALONC Average Weekly Movement | 1.7% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALONC has not had significant price volatility in the past 3 months.
Volatility Over Time: ALONC's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 236 | Philippe Genne | www.oncodesign.com |
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities.
Oncodesign Société Anonyme Fundamentals Summary
| ALONC fundamental statistics | |
|---|---|
| Market cap | €99.44m |
| Earnings (TTM) | -€6.19m |
| Revenue (TTM) | €32.67m |
3.0x
P/S Ratio-16.1x
P/E RatioIs ALONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALONC income statement (TTM) | |
|---|---|
| Revenue | €32.67m |
| Cost of Revenue | €17.60m |
| Gross Profit | €15.07m |
| Other Expenses | €21.26m |
| Earnings | -€6.19m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 46.14% |
| Net Profit Margin | -18.94% |
| Debt/Equity Ratio | 232.0% |
How did ALONC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/23 05:16 |
| End of Day Share Price | 2022/12/08 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncodesign Société Anonyme is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Waanders | Bryan Garnier & Co |
| Victor Floch | Bryan Garnier & Co |
| Fanny Meindre | CIC Market Solutions (ESN) |